First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer - Seite 2

About Bladder Cancer and Urothelial Carcinoma

Bladder cancer is the sixth most commonly occurring cancer in men, and the tenth most common cancer overall worldwide.² In 2020, 573,278 people worldwide were diagnosed with bladder cancer and 212,536 people died from their disease.³ Urothelial carcinoma (or UCC) accounts for ~90% of all bladder cancers. UCC also accounts for 10% to 15% of kidney cancers diagnosed in adults.⁴

About TLX250-CDx

TLX250-CDx (⁸⁹Zr-girentuximab) is being developed by Telix for the purpose of determining whether “indeterminate renal masses”, typically identified based on CT or MRI imaging, are either clear cell renal cell cancer (ccRCC) or non-ccRCC, using Positron Emission Tomography (PET) imaging. Girentuximab is a monoclonal antibody that targets carbonic anhydrase IX (CAIX), a cell surface target that is highly expressed in several human cancers including renal, lung and oesophageal cancers. In July 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy (BT) designation⁵ for TLX250-CDx, reflecting the significant unmet clinical need to improve the diagnosis and staging of ccRCC, the most common and aggressive form of kidney cancer.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix Corporate Contact		Telix Corporate Communications
Dr. Christian Behrenbruch Telix Pharmaceuticals Limited Managing Director and CEO Email: [e-mail]		Dr. Stewart Holmstrom Telix Pharmaceuticals Limited Director of Corporate Communications Email: [e-mail]

_______________
¹ Positron emission tomography/computed tomography
² World Cancer Research Fund (WCRF).
³ GLOBOCAN.
⁴ American Society of Clinical Oncology (ASCO).
⁵ ASX disclosure 1/07/20.